OTCMKTS:CNBX CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis → Discover How to Turn $10,000 into $1 Million (From Paradigm Press) (Ad) Free CNBX Stock Alerts $0.0094 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.0074▼$0.009450-Day Range$0.0065▼$0.014952-Week Range$0.01▼$0.05Volume308,462 shsAverage Volume272,623 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get CNBX Pharmaceuticals alerts: Email Address Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX)CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.Read More CNBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNBX Stock News HeadlinesNovember 24, 2023 | benzinga.comCNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and DatesNovember 5, 2023 | morningstar.comCNBX Pharmaceuticals Inc CNBXOctober 10, 2023 | investing.comCNBX Historical DataJuly 28, 2023 | finance.yahoo.comCNBX - CNBX Pharmaceuticals Inc.November 8, 2022 | benzinga.comCNBX Acquires A Controlling Interest In Cancer Immunotherapy DeveloperNovember 8, 2022 | finance.yahoo.comCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza BiopharmaOctober 18, 2022 | finance.yahoo.comCNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer TherapyOctober 13, 2022 | finance.yahoo.comCNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and IsraelSeptember 28, 2022 | finance.yahoo.comCNBX Pharmaceuticals Announces New Patent Granted in AustraliaSeptember 12, 2022 | reuters.comCNBX Pharmaceuticals IncAugust 16, 2022 | ca.finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBX)June 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and RevenueJune 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, PredictionsJune 7, 2022 | finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBXD)May 31, 2022 | finance.yahoo.comCNBX Pharmaceuticals Release a New Corporate PresentationMay 14, 2022 | barrons.comCNBX Pharmaceuticals Inc.May 5, 2022 | seekingalpha.comCNBX pharma granted patent in Hong Kong for cancer therapyMay 5, 2022 | finance.yahoo.comCNBX Pharmaceuticals Granted Patent in Hong KongApril 4, 2022 | msn.comNovartis to save at least $1 billion by 2024 thanks to simplified structureApril 4, 2022 | msn.comVertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killerApril 4, 2022 | cnbc.comWhat to watch today: Wall Street looks higher; Twitter soars on Elon Musk stakeApril 4, 2022 | msn.comStocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and moreApril 1, 2022 | cnbc.comCNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit TodayApril 1, 2022 | cnbc.comWhat to watch today: Wall Street set to wrap up strong month but weak quarterApril 1, 2022 | msn.comStocks making the biggest moves premarket: Walgreens, Baidu, Novavax and othersSee More Headlines Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryCannabis Current SymbolOTCMKTS:CNBX CUSIPN/A CIK1343009 Webwww.cannabics.com Phone(877) 424-2429FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Gabriel Yariv (Age 48)President, COO & Executive Chairman Comp: $241.67kMr. Uri Ben-Or CPA (Age 54)CPA, M.B.A., MBA, Chief Financial Officer Comp: $40.32kMr. Eyal Barad (Age 59)Co-Founder, CEO & Director Comp: $269.15kDr. Sanja Goldberg (Age 48)Chief Technology Officer Comp: $48.12kNoam PermontVice President of Public Relations & Investor RelationsDr. Sigalit Ariely-Portnoy Ph.D. (Age 60)Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board Dr. Tal Mofkadi Ph.D.Financial Advisor & Member of Advisory BoardMr. Yasha Borstein (Age 61)Chief Data Officer Dr. Yaakov Waksman (Age 72)Head of Cannabidiol Research Dr. Ilya Reznik M.D.Head of Neuropsychiatry DevelopmentMore ExecutivesKey Competitors1PM IndustriesOTCMKTS:OPMZAcquired SalesOTCMKTS:AQSPAmerican CannabisOTCMKTS:AMMJAmeriCannOTCMKTS:ACANCannabis SativaOTCMKTS:CBDSView All Competitors CNBX Stock Analysis - Frequently Asked Questions How have CNBX shares performed in 2024? CNBX Pharmaceuticals' stock was trading at $0.0142 at the beginning of the year. Since then, CNBX stock has decreased by 33.8% and is now trading at $0.0094. View the best growth stocks for 2024 here. When did CNBX Pharmaceuticals' stock split? CNBX Pharmaceuticals shares reverse split on Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of CNBX Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Organigram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA). How do I buy shares of CNBX Pharmaceuticals? Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CNBX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNBX Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.